In a new study, obese kids who used GLP-1 weight-loss drugs had a 33% decline in their risk for thoughts of suicide and suicide attempts compared to adolescents who didn't.

However, GLP-1-based therapies aren't going to be the only option in the weight loss medicines market forever. Some companies are pursuing other approaches that could be even more effective or complementary to the existing interventions.

Fewer than 20% of large employers are covering GLP-1 weight loss drugs like Ozempic, a new KFF analysis shows.

WeightWatchers said it will sell compounded versions of semaglutide — the key ingredient in Novo Nordisk's Ozempic and Wegovy.

The embattled diet brand said it is adding a compounded weight-loss drug in accordance with FDA rules and manufacturing standards. WeightWatchers announced on Tuesday that it will offer a compounded version of Novo Nordisk‘s popular weight-loss drug Wegovy as part of its weight-management programs,

According to the Congressional Budget Office, the average 2034 per-user effect could be $650 in savings and $4,300 in costs for Medicare, but this could have a big effect on all employers health plans as well.

Key Takeaways Hims & Hers shares gained Monday after the Food and Drug Administration said compounding pharmacies could continue to produce copycat weight-loss drugs while it reconsiders whether there is a shortage.

Hims & Hers Health (NYSE:HIMS) is up ~10% in Monday morning trading following a recent lawsuit challenging the U.S. FDA's  decision to remove Eli Lilly's (NYSE:LLY) tirzepatide from a drug shortages list.